Product Description
Erlotinib Hydrochloride is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It blocks EGFR signaling pathway, inhibits cancer cell proliferation, angiogenesis, invasion and metastasis, and induces tumor cell apoptosis.
It is a classic oral targeted therapeutic agent, widely applied in EGFR mutation-positive malignant tumors with definite curative effect and controlled adverse reactions.
Indications
- First-line, maintenance or second-line and beyond treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC)
- Combined regimen treatment for advanced pancreatic cancer
Directions for Use
Oral administration, swallow whole with water. Take at least 1 hour before or 2 hours after food. 150 mg once daily, follow oncologist’s prescription strictly. Do not crush, chew or split the tablet.
Product Features
- Standard 150mg clinical targeted dose
- Oral EGFR targeted inhibitor, convenient administration
- Precise action on EGFR mutant tumor cells
- Improve progression-free survival and quality of life
- Mature clinical application with stable efficacy
Storage
Store sealed in a cool dry place, protect from light and moisture. Keep away from high temperature.
Warnings
- Contraindicated in patients with hypersensitivity to erlotinib hydrochloride or any excipients.
- May cause interstitial lung disease; monitor respiratory symptoms closely.
- Common side effects: rash, diarrhea, dry skin, oral ulceration.
- Avoid concurrent use with strong CYP3A4 inhibitors/inducers without medical advice.
- Hepatic and renal function should be monitored regularly during treatment.
- Not recommended for pregnant, lactating women and children.
- Keep out of reach of children.
